Table 1.
Antibiotics susceptibilities of all E. coli isolates in this study.
| Antimicrobial Agents | Number of Resistant Isolates (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total (n = 283) |
Mode of Acquisition | Site of Infection c | Facility e | |||||||||
| Community-onset (n = 150) |
Hospital-onset (n = 102) |
LTCF b-onset (n = 31) |
P | UTI d (n = 129) |
Non-UTI (n = 154) |
P | SMC (n = 114) |
SCH (n = 107) |
KUAH (n = 62) |
P | ||
| Fosfomycin | 19 (6.7) | 9 (6.0) | 7 (6.9) | 3 (10.0) | 0.384 | 5 (3.9) | 14 (9.1) | 0.042 | 4 (3.5) | 9 (8.4) | 6 (9.7) | 0.054 |
| Ciprofloxacin | 181 (64.0) | 72 (48.0) | 70 (68.6) | 22 (71.0) | 0.285 | 70 (72.9) | 111 (59.4) | 0.023 | 67 (58.8) | 62 (57.9) | 52 (83.9) | 0.008 |
| Cefepime | 117 (41.3) | 48 (32.0) | 55 (53.9) | 14 (45.2) | 0.008 | 45 (34.9) | 72 (46.8) | 0.115 | 45 (39.5) | 40 (37.4) | 32 (51.6) | 0.022 |
| Cefixime | 131 (46.3) | 58 (38.7) | 57 (55.9) | 16 (51.6) | 0.033 | 54 (48.9) | 77 (50.0) | 0.363 | 48 (42.1) | 45 (42.1) | 38 (61.3) | 0.062 |
| P/T a | 88 (31.1) | 38 (25.4) | 42 (41.2) | 8 (25.8) | 0.025 | 42 (32.6) | 46 (29.9) | 0.813 | 49 (43.0) | 34 (31.8) | 5 (8.1) | <0.001 |
| Amikacin | 6 (2.1) | 0 | 4 (3.9) | 2 (6.5) | 0.017 | 4 (3.1) | 2 (1.3) | 0.534 | 5 (4.4) | 0 | 1 (1.6) | 0.116 |
| Ertapenem | 7 (2.5) | 1 (0.7) | 6 (5.9) | 0 | 0.012 | 4 (3.1) | 3 (1.9) | 0.880 | 1 (0.9) | 3 (2.8) | 3 (4.8) | 0.244 |
| Colistin | 30 (10.6) | 12 (8.0) | 15 (14.7) | 3 (9.7) | 0.219 | 18 (14.0) | 12 (7.8) | 0.121 | 20 (17.5) | 7 (6.5) | 3 (4.8) | 0.007 |
| Tigecycline | 3 (1.1) | 0 | 2 (2.0) | 1 (3.2) | 0.075 | 2 (1.5) | 1 (0.6) | 0.593 | 0 | 0 | 2 (3.2) | 0.117 |
a P/T, piperacillin/tazobactam. b LTCF, long-term care facility. c All patients accompanied by E. coli infection. d UTI, urinary tract infection. e SMC, Samsung Medical Center; SCH, Samsung Changwon Hospital; KUAH, Korea University Ansan Hospital.